Analysis of trial confirms efficacy of esketamine nasal spray in TRD
The Brown University Psychopharmacology Update March 1, 2025 DOI: 10.1002/pu.31276 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Secondary sensitivity analyses of a Phase 3b randomized trial Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression (TRD) |
| Intervention | Esketamine nasal spray |
| Topics | Esketamine |
| Key findings | Sensitivity analyses of the Phase 3b ESCAPE-TRD trial indicate that esketamine nasal spray was consistently more efficacious than extended-release quetiapine in patients with treatment-resistant depression, using multiple thresholds for remission and relapse. Specific effect sizes and numerical results are not reported in the text. |
Abstract
Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended‐release quetiapine in patients with treatment‐resistant depression (TRD). The additional analyses of the ESCAPE‐TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in The British Journal of Psychiatry.